Melane Sampson, Author at BioTuesdays

Developments

Hoth reports positive interim results from trial of HT-001 in cancer patients

Hoth Therapeutics (NASDAQ: HOTH) has announced 100% clinical response and approximately 50% reduction in disease severity in the open-label pharmacokinetic (PK) cohort of its ongoing CLEER-001 clinical trial evaluating...

January 22, 2026

Executive Moves

Zura names Dr. Sandeep Kulkarni as CEO

Zura Bio (NASDAQ: ZURA) has appointed Sandeep Kulkarni, MD, as chief executive officer (CEO), effective today. Dr. Kulkarni will continue to serve as a director of Zura. He succeeds Kim Davis, JD, who has served as...

January 21, 2026

Developments

Actuate to advance Elraglusib tablet to Phase 1/2 program in refractory cancers

Actuate Therapeutics (NASDAQ: ACTU) has announced plans to initiate a Phase 1/2 clinical program evaluating the oral tablet dosage form of elraglusib in patients with advanced cancer. According to Actuate, the goal of...

January 21, 2026

Feature

First Ascent changing the cancer care narrative with functional precision medicine

Closely held First Ascent Biomedical is working to redefine how oncologists select therapies by pairing genomics with a proprietary live-cell testing platform that evaluates how an individual patient’s cancer responds...

January 20, 2026

Developments

BioNxt reports superior bioavailability of cladribine sublingual ODF

BioNxt Solutions (CSE: BNXT; OTCQB: BNXTF; FSE: BXT) has announced that it has completed a large-mass porcine comparative pharmacokinetic study and received preliminary results evaluating the absorption of cladribine...

January 19, 2026

Executive Moves

Arch names Dr. Patrick Vink as chairman of BOD

Arch Biopartners (TSXV: ARCH; OTCQB: ACHFF) has announced the appointment of Dr. Patrick Vink as chairman of the company’s board of directors (BOD), effective January 15, 2026. Dr. Vink, MD, MBA, has been an advisor to...

January 16, 2026

Developments

Profusa initiates first commercial revenue with healthcare research offerings launch

Profusa (NASDAQ: PFSA) has announced the launch of its healthcare research version of its Lumee tissue oxygen monitoring into the contract research organizations (CRO) market, which is expected to generate immediate...

January 16, 2026

Developments

GT submits IND for GTB-5550 TriKE in solid tumors

GT Biopharma (NASDAQ: GTBP) has announced that it submitted an investigational new drug (IND) application to the FDA in December 2025 for GTB-5550 TriKE, a B7-H3-targeted natural killer (NK) cell engager for the...

January 15, 2026

Developments

Frontiers in Oncology to publish BioMark’s research on ML model for lung cancer detection

BioMark Diagnostics (CSE: BUX; FSE: 20B; OTCQB: BMKDF) has announced that the peer-reviewed journal Frontiers in Oncology has accepted for publication the company’s research on a machine learning (ML) predictive model...

January 15, 2026

Developments

Mount Sinai becomes first in NYC to deliver incision-free, MRI-guided prostate treatment with Profound’s TULSA-PRO

Profound Medical (NASDAQ: PROF; TSX: PRN) has announced that the world-renowned Mount Sinai Hospital, Metro New York (NYC), has successfully treated its first prostate cancer patient with the TULSA-PRO system. The TULSA...

January 15, 2026

Author - Melane Sampson

Hoth reports positive interim results from trial of HT-001 in cancer patients

Zura names Dr. Sandeep Kulkarni as CEO

Actuate to advance Elraglusib tablet to Phase 1/2 program in refractory cancers

First Ascent changing the cancer care narrative with functional precision medicine

BioNxt reports superior bioavailability of cladribine sublingual ODF

Arch names Dr. Patrick Vink as chairman of BOD

Profusa initiates first commercial revenue with healthcare research offerings launch

GT submits IND for GTB-5550 TriKE in solid tumors

Frontiers in Oncology to publish BioMark’s research on ML model for lung cancer detection

Mount Sinai becomes first in NYC to deliver incision-free, MRI-guided prostate treatment with Profound’s TULSA-PRO

Subscribe